3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Antimalarial drug development faces high costs and failure risks.
• Existing drugs like ELQ-300 and its prodrug ELQ-331 show promise but require continuous innovation.
• Multidrug-resistant Plasmodium falciparum necessitates the development of novel therapeutic agents.

Purpose of the Study:

• To introduce ELQ-596, a novel 3-biaryl-ELQ derivative with enhanced antimalarial activity.
• To evaluate ELQ-598, a prodrug of ELQ-596, for improved efficacy and pharmacokinetic properties.
• To explore the structure-activity relationships of a new series of next-generation ELQ antimalarials.

Main Methods:

• Synthesis and characterization of 3-biaryl-ELQ compounds, including ELQ-596 and ELQ-598.
• In vitro testing against multidrug-resistant Plasmodium falciparum strains.
• In vivo efficacy studies in murine malaria models.
• Pharmacokinetic assessments, including bloodstream half-life determination in mice.

Main Results:

• ELQ-596 demonstrated enhanced in vitro potency against resistant malaria parasites.
• ELQ-598 showed 4- to 10-fold greater efficacy than ELQ-331 in murine malaria models.
• ELQ-596 exhibited a longer bloodstream half-life in mice compared to its progenitor.
• Preliminary structure-activity relationship data for potency, selectivity, pharmacokinetics, and safety were obtained.

Conclusions:

• ELQ-596 and its prodrug ELQ-598 represent a promising new class of next-generation antimalarial drugs.
• These compounds demonstrate potential for improved efficacy and convenient dosing regimens (e.g., once-monthly).
• Further development of these 3-biaryl-ELQs could lead to more effective strategies for malaria prevention and treatment.